PD-L1 expression and clinical outcomes with targeted therapy

A recent study published in Clinical Cancer Research analysed tumour tissue samples obtained in a clinical trial to investigate how the expression of the PD-L1 receptor on the tumour cells influenced outcomes in patients with metastatic renal cell carcinoma (RCC) receiving targeted therapy. Positive expression of the PD-L1 receptor on RCC tumour cells was associated […]

read more

ASCO GU 2019: Early tumour shrinkage and improved survival with cabozantinib

The results from the following study were presented at the American Society for Clinical Oncology (ASCO) genitourinary (GU) conference in San Francisco in February 2019. Dr Ignacio Durán, of the Hospital Universitario Marqués de Valdecilla in Spain, presented new results from the phase 3 METEOR trial showing that patients with advanced renal cell carcinoma (RCC) treated with cabozantinib […]

read more

Current role of mTOR inhibitors in metastatic kidney cancer

The following video interview with Dr Eric Jonasch, from the MD Anderson Cancer Center, Houston, Texas, describes the current role of mTOR inhibitors for the treatment of metastatic renal cell carcinoma (mRCC). Watch the video interview on Practice Update here

read more

Potential biomarkers may predict response to TKIs in metastatic kidney cancer

A recent study published in Clinical Cancer Research and conducted in France has identified potential biological markers that are related to the formation of new blood vessels (angiogenesis) and regulated by the levels of oxygen reaching the tissues (hypoxia). These biomarkers have been found to be strong predictors of response, progression-free survival (PFS), and overall survival […]

read more

Cabozantinib significantly improves overall survival in people with previously treated advanced kidney cancer

Cabozantinib significantly improves overall survival in previously treated patients with advanced renal cell carcinoma (RCC) compared to everolimus, with consistent results after long-term follow-up. Results from a second interim analysis of the phase 3 METEOR trial have been published in the British Journal of Cancer, showing cabozantinib significantly improved overall survival compared with everolimus in […]

read more

Status of adjuvant therapy for the treatment of kidney cancer

Dr Naomi Haas from Abramson Cancer Centre, Philadelphia, presented an overview of adjuvant therapy with vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs) in patients with high-risk renal cell carcinoma (RCC) at the American Society for Clinical Oncology Genitourinary (ASCO GU) 2018 meeting in San Francisco this month. Over the past few years, three […]

read more

The future of immuno-oncology in kidney cancer

In his keynote lecture at the American Society for Clinical Oncology Genitourinary (ASCO GU) 2018 meeting in San Francisco this month, Dr Bernard Escudier from the Institut Gustave Roussy in Villejuif, France, discussed the future of immuno-oncology in renal cell carcinoma (RCC). The current landscape of immune-oncology has been shaped by the results from the […]

read more

New drug shows promise in combination with cabozantinib for the treatment of advanced kidney cancer

Results from a phase 1 clinical trial looking at CB-839, a first in class glutaminase inhibitor, in combination with cabozantinib, an oral tyrosine kinase inhibitor (TKI), for the treatment of advanced renal cell carcinoma (RCC) have been released. Preliminary results show the combination demonstrated a 40% overall response rate in advanced clear cell RCC patients, […]

read more

Quality of life outcomes similar for cabozantinib and everolimus

Data from the phase 3 METEOR trial published in the Journal of Clinical Oncology recently show that treatment of advanced kidney cancer patients with cabozantinib resulted in similar quality of life (QoL) outcomes as for patients treated with everolimus. Cabozantinib also improved progression-free survival (PFS), overall survival (OS), and overall response rate (ORR) compared with everolimus. The […]

read more

Cabozantinib more effective than everolimus for treatment of kidney cancer bone metastases

Cabozantinib (Cabometyx) was more effective than everolimus (Afinitor) in people with advanced renal cell carcinoma (RCC) and bone metastases, according to a subgroup analysis of the METEOR clinical trial carried out by researchers at the Gustave Roussy Institute in Villejuif, France and published in Journal of Clinical Oncology. Progression-free survival in people with bone metastases was […]

read more
Showing 11 to 20 of 46 results
  TOP